Market closed
Vera Therapeutics/$VERA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Vera Therapeutics
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Ticker
$VERA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
82
Website
VERA Metrics
BasicAdvanced
$2.7B
Market cap
-
P/E ratio
-$2.62
EPS
1.02
Beta
-
Dividend rate
Price and volume
Market cap
$2.7B
Beta
1.02
52-week high
$50.78
52-week low
$14.20
Average daily volume
579K
Financial strength
Current ratio
13.759
Quick ratio
13.351
Long term debt to equity
18.349
Total debt to equity
18.996
Interest coverage (TTM)
-15.23%
Management effectiveness
Return on assets (TTM)
-33.37%
Return on equity (TTM)
-65.11%
Valuation
Price to book
8
Price to tangible book (TTM)
8
Price to free cash flow (TTM)
-17.812
Growth
Earnings per share change (TTM)
-1.76%
3-year earnings per share growth (CAGR)
-28.51%
What the Analysts think about VERA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Vera Therapeutics stock.
VERA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
VERA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
VERA News
AllArticlesVideos
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Vera Therapeutics stock?
Vera Therapeutics (VERA) has a market cap of $2.7B as of December 21, 2024.
What is the P/E ratio for Vera Therapeutics stock?
The price to earnings (P/E) ratio for Vera Therapeutics (VERA) stock is 0 as of December 21, 2024.
Does Vera Therapeutics stock pay dividends?
No, Vera Therapeutics (VERA) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Vera Therapeutics dividend payment date?
Vera Therapeutics (VERA) stock does not pay dividends to its shareholders.
What is the beta indicator for Vera Therapeutics?
Vera Therapeutics (VERA) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.